Assessment of hepatocyte growth factor in ovarian cancer mortality.

Journal Article (Journal Article)

BACKGROUND: Invasive ovarian cancer is a significant cause of gynecologic cancer mortality. METHODS: We examined whether this mortality was associated with inherited variation in approximately 170 candidate genes/regions [993 single-nucleotide polymorphisms (SNPs)] in a multistage analysis based initially on 312 Mayo Clinic cases (172 deaths). Additional analyses used The Cancer Genome Atlas (TCGA; 127 cases, 62 deaths). For the most compelling gene, we immunostained Mayo Clinic tissue microarrays (TMA, 326 cases) and conducted consortium-based SNP replication analysis (2,560 cases, 1,046 deaths). RESULTS: The strongest initial mortality association was in HGF (hepatocyte growth factor) at rs1800793 (HR = 1.7, 95% CI = 1.3-2.2, P = 2.0 × 10(-5)) and with overall variation in HGF (gene-level test, P = 3.7 × 10(-4)). Analysis of TCGA data revealed consistent associations [e.g., rs5745709 (r(2) = 0.96 with rs1800793): TCGA HR = 2.4, CI = 1.4-4.1, P = 2.2 × 10(-3); Mayo Clinic + TCGA HR = 1.6, CI = 1.3-1.9, P = 7.0 × 10(-5)] and suggested genotype correlation with reduced HGF mRNA levels (P = 0.01). In Mayo Clinic TMAs, protein levels of HGF, its receptor MET (C-MET), and phospho-MET were not associated with genotype and did not serve as an intermediate phenotype; however, phospho-MET was associated with reduced mortality (P = 0.01) likely due to higher expression in early-stage disease. In eight additional ovarian cancer case series, HGF rs5745709 was not associated with mortality (HR = 1.0, CI = 0.9-1.1, P = 0.87). CONCLUSIONS: We conclude that although HGF signaling is critical to migration, invasion, and apoptosis, it is unlikely that HGF genetic variation plays a major role in ovarian cancer mortality. Furthermore, any minor role is not related to genetically-determined expression. IMPACT: Our study shows the utility of multiple data types and multiple data sets in observational studies.

Full Text

Duke Authors

Cited Authors

  • Goode, EL; Chenevix-Trench, G; Hartmann, LC; Fridley, BL; Kalli, KR; Vierkant, RA; Larson, MC; White, KL; Keeney, GL; Oberg, TN; Cunningham, JM; Beesley, J; Johnatty, SE; Chen, X; Goodman, KE; Armasu, SM; Rider, DN; Sicotte, H; Schmidt, MM; Elliott, EA; Høgdall, E; Kjær, SK; Fasching, PA; Ekici, AB; Lambrechts, D; Despierre, E; Høgdall, C; Lundvall, L; Karlan, BY; Gross, J; Brown, R; Chien, J; Duggan, DJ; Tsai, Y-Y; Phelan, CM; Kelemen, LE; Peethambaram, PP; Schildkraut, JM; Shridhar, V; Sutphen, R; Couch, FJ; Sellers, TA; Ovarian Cancer Association Consortium,

Published Date

  • August 2011

Published In

Volume / Issue

  • 20 / 8

Start / End Page

  • 1638 - 1648

PubMed ID

  • 21724856

Pubmed Central ID

  • PMC3153603

Electronic International Standard Serial Number (EISSN)

  • 1538-7755

Digital Object Identifier (DOI)

  • 10.1158/1055-9965.EPI-11-0455


  • eng

Conference Location

  • United States